Losartan Does Not Reduce Lung Injury in Hospitalized COVID-19 Patients
Administration of losartan to hospitalized patients with COVID-19 and acute lung injury is not efficacious for reducing lung injury.
Administration of losartan to hospitalized patients with COVID-19 and acute lung injury is not efficacious for reducing lung injury.
A 67-year-old man presents for his yearly wellness visit and reports some shortness of breath since the Sonoma-Napa wildfires but otherwise feels well.